NATURAL RESISTANCE TO HIV INFECTION LEADING TO NEW APPROACHES TO THERAPY
R. Gallo*, Baltimore MD, USA

08:30 - 09:30

DEEP-SEATED FUNGAL INFECTION IN THE IMMUNOCOMPROMISED HOST: EPIDEMIOLOGY & CLINICAL PRESENTATIONS
M. Weinberger*, Israel

THE CONTINUING SAGA OF DIFFICULT TO ERADICATE CANDIDA INFECTIONS

J. Sobel*, USA
PREVENTION OF OPPORTUNISTIC FUNGAL DISEASE IN NEUTROPENIC PATIENTS B. De Pauw*, The Netherlands

THE CHALLENGE OF INVASIVE ASPERGILLOSIS: LIGHT AT THE END OF THE TUNNEL
B. Dupont*, France

ANTIBIOTIC MARKER GENES IN PLANT GENETICS
M.J. Gasson*, UK

FUTURE PROBLEMS USING ANTIBIOTIC RESISTANCE GENES AS MARKERS IN PLANT GENETICS
J.-C. Pechere*, Switzerland

ANTIBIOTICS IN FOOD ANIMALS: ARE THEY A RISK TO MAN?
N.A. Simmons*, UK

MULTIPLE ANTIBIOTIC RESISTANCE IN SALMONELLA - THE CURRENT SITUATION OF THIS GLOBAL EPIDEMIC
E.J. Threlfall*

CLINICAL SIGNIFICANCE OF HIV DRUG RESISTANCE AND CROSS RESISTANCE
M.A. Wainberg*, Montreal PQ, Canada

HIV DRUG THERAPY: OBSTACLES, PERSPECTIVES AND NEW COCKTAILS
S. Staszewski*, Frankfurt, Germany

RECENTLY COMPLETED ANTI RETROVIRAL DRUG STUDIES: WHERE ARE WE HEADING?
J. Gatell*, Barcelona, Spain

REGIONAL DIFFERENCES IN HIV DISEASE MANIFESTATIONS IN EUROPE
J. Kosmidis*, Athens, Greece

RESISTANT GRAM POSITIVE ORGANISMS
F. Baquero*, Spain

ACINETOBACTER
E. Bergogne Berezin*, France

FISH-BORNE PATHOGENS - VIBRIO VULNIFICUS
N. Bisharat*, Israel

CAT SCRATCH DISEASE
M. Giladi*, Israel

KINGELLA INFECTIONS
P. Yagupsky*, Israel

STREPTOCOCCUS INIAE
H. BERCOVIER*, Israel

EPIDEMIOLOGY & TREATMENT OF |FIHELICOBACTER PYLORI|FH INFECTIONS F. Megraud*, Bordeaux, France

CATHETHER RELATED URINARY TRACT INFECTION
L.E. Nicolle*, Winnipeg MB, Canada

POSTMENOPAUSAL URINARY TRACT INFECTION
R. Raz*, Israel

MANAGEMENT STRATEGIES OF URINARY TRACT INFECTION IN COMMUNITY
H. Giamarellou*, Greece

LABORATORY DIAGNOSIS OF URINARY TRACT INFECTION
M. Pezzlo*

LIPOSOME ENCAPSULATION OF DRUGS: FORMULATION ASPECTS
H. Barenholz*

LIPOSOMES IN THE THERAPY OF INFECTIOUS DISEASES
G. Storm*, The Netherlands

CLINICAL PHARMACOLOGY OF LIPOSOMAL ANTHRACYCLINES
A. Gabizon*, Israel

PEGYLATED LIPOSOMAL DOXORUBICIN IN TREATMENT OF CANCER
S. Stewart*, UK

TOWARDS ANTI-ADHESION THERAPY OF INFECTIOUS DISEASES 5002
I. Ofek*, Israel

TREATMENT OF INFECTIONS FOLLOWING TRAUMA
E.P. Dellinger*, USA

TREATMENT OF SEVERE INTRA-ABDOMINAL INFECTIONS
S. Geroulanos*, Greec

EMERGING RESISTANCE PATTERNS AMONGST PATHOGENS CAUSING INTRA-ABDOMINAL INFECTIONS
D.M. Livermore*, UK

DOSAGE OF CARBAPENEMS IN THE ICU - A META-ANALYSIS
J.S. Solomkin*, USA

THE DIAGNOSIS OF VENTILATOR ASSOCIATED PNEUMONIA
J. Chastre*, France

RISK FACTORS FOR NOSOCOMIAL PNEUMONIAS
D.E. Craven*, USA

THE TREATMENT OF NOSOCOMIAL PNEUMONIAS WITH CEFEPIME
G. Beaucaire, France

EPIDEMIOLOGY AND MOLECULAR EPIDEMIOLOGY OF HIV INFECTION IN THE MEDITERRANEAN REGION
S. Maayan*, Jerusalem, Israel

PATHOGENESIS OF AIDS: LESSONS FROM THE ETHIOPIAN IMMIGRATION TO ISRAEL
Z. Bentwich*, Rehovot, Israel

MULTI-PHASIC HIV VIRAL LOAD DECLINE DURING THERAPY: FROM VERY RAPID TO VERY SLOW
A. Neuman*, Ramat Gan, Israel

MATERNAL TRANSMISSION OF HIV. NEW THOUGHTS AND DIRECTIONS 4006
S. Nachman*, Stony Brook NY, USA

TREATMENT CHALLENGES IN THE PEDIATRIC AGE GROUP 4042
R. Yogev*, Chicago IL, USA

ETIOLOGY OF RESPIRATORY INFECTIONS
P. Hawkey*, UK

PHARMACODYNAMICS OF 4-FLUOROQUINOLONES IN LOWER RESPIRATORY TRACT INFECTIONS
I.M. Gould*, Aberdeen, UK

SUMMARY OF MOXIFLOXACIN DATA
M. Springslkee*, Germany

Title to be advised
J. Rowe*

Title to be advised
S. Slavin*

INFECTIONS IN BONE MARROW TRANSPLANT PATIENTS TODAY
D. Engelhard*, Israel

NEW AND CURRENT APPROACHES TO EMPIRICAL TREATMENT OF FEBRILE NEUTROPENIA
H. Gaya*, UK

NEW PATHOGENS IN GRANULOCYTOPENIC PATIENTS 4051
S. Zinner*

IN-VITRO AND PHARMACOKINETIC PROFILE OF TROVAFLOXACIN
H. Giamarellou*, Greece

TROVAFLOXACIN IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA
To Be Announced

TROVAFLOXACIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA 4053
H. Lode*, Germany

USE OF TROVAFLOXACIN IN THE MANAGEMENT OF SURGICAL AND INTRA-ABDOMINAL INFECTIONS
I. Sayek*, UK

CONCLUDING REMARKS
To Be Announced

FUNGAL INFECTIONS INLEUKEMIC PATIENTS: THE USUAL AND UNUSUAL
V. Krcmery*, Slovak Republic

EPIDEMIOLOGY AND RISK FACTORS FOR NOSOCOMIAL CANDIDA INFECTIONS
M. Weinberger*, Israel

THE USE OF AMBISOME IN SOLID ORGAN TRANSPLANT
J. Tollemar*

THE USE OF AMBISOME IN NEONATES
E. Leibovitz*, Israel

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
P. Saikku*, Finland

ANIMAL MODELS
J. Orfila*, France

CHLAMYDIA PNEUMONIAE AND COMMUNITY ACQUIRED PNEUMONIA
D. Lieberman*, Israel

THERAPY OF CHLAMYDIAL INFECTIONS
H. Akalin*, Turkey

ANTIBIOTICS - QUO VADIS?
F. Baquero*, Spain

MORE INFECTION-PRONE PATIENTS; NEWER RISK FACTORS
E. Rubinstein*, Israel

DIFFICULT TO TREAT NOSOCOMIAL PATHOGENS: TRENDS IN ANTIBIOTIC RESISTANCE
G.C. Schito*, A. Pesce*, Italy

ACQUISITION OF NEW RESISTANCE TRAITS: BACTERIAL STRATEGIES
S. Stefani*, G. Nicoletti*, Italy

FUTURE THERAPEUTIC TRENDS
C. Carbon*, France

ANTIBIOTIC RESISTANCE AMONG PATHOGENS CAUSING ACUTE OTITIS MEDIA
P. Yagupsky*, Israel

THE CHALLENGE OF ANTIBIOTIC TREATMENT OF ACUTE OTITIS IN THE ERA RESISTANCE
R. Dagan*, Israel

ANTIBIOTIC RESISTANCE AND THE OUTCOME OF ACUTE OTITIS MEDIA
P. Gehanno*, France

MICROBIOLOGY OF BRUCELLOSIS
O. Ang*, Turkey

CLINICAL FEATURES OF BRUCELLOSIS
J. Kosmidis*, Greece

MODERN TREATMENT OF BRUCELLOSIS
R. Lang*, Israel

RICKETTSIOSIS IN ISRAEL
A. Keysary*, Ness Ziona, Israel

MALARIA PROPHYLAXIS: GUIDELINES AND CONTROVERSIES
R. Steffen*, Switzerland

A COMPUTER PROGRAM FOR INFORMATICS, DIAGNOSIS AND SIMULATION IN GEOGRAPHIC MEDICINE
S.A. Berger, Israel

HEPATITIS A VACCINE: NOT ONLY FOR THE TRAVELLERS
S. Waner*, South Africa

PROPHYLAXIS AND VACCINATION CONSIDERATIONS FOR INTERNATIONAL TRAVEL WITH CHILDREN
M. Efrat*, Haifa, Israel

Title to be advised
M. Levine*, Canada

Title to be advised
Tursz*

Title to be advised
T. Peretz*

HELICOBACTER
Chowers*, Israel

AIDS & CANCER
I. Levi*, Israel

HEPATITIS B VIRUS AND CANCER
Y. Ilan, Israel

HP VIRUS & CANCER
Ben Baruch*

IMMUNIZATION AGAINST TUBERCULOSIS - NEW THROUGHTS
H. BERCOVIER*, Israel

MOLECULAR EPIDEMIOLOGY OF TUBERCULOSIS
G. Rahav*, Israel

TUBERCULOSIS IN THE MEDITERRANEAN
S. Schonwald*, Croatia

TUBERCULOSIS IN AN IMMIGRANT SOCIETY 4086
D. Weiler*, Israel

EPIDEMIOLOGY OF COMMUNITY ACQUIRED PNEUMONIA
G.J. Huchon*, France

COST DRIVERS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA
L.A. Mandell*, Canada

TREATMENT APPROACHES IN COMMUNITY ACQUIRED PNEUMONIA
To Be Announced

BACTERIAL RESISTANCE IN PORTUGAL
H. De Lencastre*, Portugal

BACTERIAL RESISTANCE IN ITALY
G.C. SCHITO*, Italy

BACTERIAL RESISTANCE IN ISRAEL
N. Keller*, Israel

BACTERIAL RESISTANCE IN TURKEY
S. Unal*, Turkey

MANAGEMENT GUIDELINES
C. Carbon*, France

SHORT COURSE OF THERAPY FOR ENDOCARDITIS
J.M. Miro*, Spain

ECHOCARDIOGRAPHY
Z. Vered*, Israel

FUNGAL ENDOCARDITIS
E. Rubinstein*, Israel

CLINICAL AND LABORATORY FEATURES OF INFECTIVE ENDOCARDITIS (IE) IN INFANTS AND YOUNG CHILDREN
S. Ashkenazi*, Z. Samra, O. Levy, L. Blieden, Petah Tikva, Israel